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CONCLUSIONS: Schizophrenic outpatients report better
subjective feelings about medication use after switching to
ziprasidone. These findings have implications for greater
patient compliance with ziprasidone and, possibly, for de-
creased relapse rates and health-care resource use.
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OBJECTIVE: The purpose of this analysis was to de-
scribe and compare patterns of drug selection, dosing,
and utilization among depressed patients treated with
SSRIs (citalopram, fluoxetine, paroxetine, and sertraline)
and venlafaxine in US managed care.
METHODS: Symmetry Health Data Systems’ Episode
Treatment Group methodology was applied to PharMet-
rics’ Integrated Outcomes Database to identify adult sub-
jects (18 years.) diagnosed with depressive disorder and
treated with one of the study medications between Janu-
ary 1, 1998 and June 30, 1999. Prescription claims
records were used to identify patterns of drug selection,
dosing, and utilization (medication persistence, augmen-
tation, switching, and time to change) for each medica-
tion cohort. Descriptive statistics were used to character-
ize drug selection and dosing patterns, and parametric
and nonparametric methods (ANOVA and chi-square)
were used to compare utilization indicators across study
groups.
RESULTS: Twelve thousand twenty six patients met in-
clusion criteria. The study cohorts were demographically
similar. Index antidepressant drug prescriptions were for
citalopram (6.2%), fluoxetine (24.6%), paroxetine (29.5%),
sertraline (33.4%), and venlafaxine (6.2%). Citalopram pa-
tients more often started (86.7%) and ended (78.4%) on the
lowest available dose. Each cohort showed similar patterns
of dosage titration/adjustment. The mean number of pre-
scriptions was similar across cohorts; citalopram-treated
patients had a significantly higher rate of persistence
(mean  118.3 days) than those treated with paroxetine
(106.5), sertraline (108.8), and venlafaxine (108.2) cohorts
(p  .001). Augmentation and switching rates were similar
across cohorts; citalopram patients whose therapy changed
had a significantly longer time to change (mean  80.9
days) than fluoxetine (76.8 days, p  0.02), paroxetine
(72.1 days, p .001), sertraline (69.6 days, p  .001), or
venlafaxine (66.8 days, p  .001) patients.
CONCLUSIONS: Of the antidepressants evaluated, cit-
alopram was most frequently prescribed at the lowest
available dose. Persistence rates were also highest with
citalopram. Clinicians and payers should consider differ-
ences in dosing and persistence to provide optimal care
and benefits for depressed patients.
PMH5
THE COST-EFFECTIVENESS OF QUETIAPINE IN 
THE TREATMENT OF SCHIZOPHRENIC 
PATIENTS PARTIALLY RESPONSIVE TO 
PREVIOUS ANTIPSYCHOTICS—AN ECONOMIC 
ANALYSIS OF THE PRIZE STUDY
Tilden D1, Aristides M2, Meddis D3, Burns T4
1M-TAG Limited, Chatswood, New South Wales, Australia; 2M-
TAG Limited, London, UK; 3AstraZeneca, Macclesfield, Cheshire, 
UK; 4St Georges Hospital Medical School, London, UK
OBJECTIVE: Psychiatrists often see patients who show
only a partial response to conventional antipsychotics.
This study assessed the cost-effectiveness and economic
impact of quetiapine treatment in this clinically impor-
tant patient population.
METHODS: A decision-analytic model with Markov
processes was constructed to assess the costs and health
benefits of quetiapine and haloperidol treatment over a
five-year period in a UK National Health Service (NHS)
setting. Response to medication and incidence of extra
pyramidal symptoms (EPS), were derived from a prospec-
tive, double blind, randomized clinical trial, the PRIZE
study. Transition probabilities used in the model were de-
rived from a thorough review of the literature and expert
opinion. Resource use unit costs were taken from the lit-
erature. Discount rates of 6% were applied to costs and
1.5% to outcomes as recommended in the UK by the Na-
tional Institute of Clinical Excellence.
RESULTS: This model found the overall cost of quetia-
pine treatment per patient to be comparable with the cost
of treatment with haloperidol over a five-year period
(£37,379 quetiapine versus £37,596 haloperidol). Hospi-
talization and institutionalization costs were £1,911 less
with quetiapine. Outpatient cost savings was estimated at
£642 with quetiapine per five years. Over the five-year
course of the model, the short-term clinical benefits
shown in the PRIZE study lead to quetiapine-treated pa-
tients experiencing fewer relapses and responding to
treatment for a longer time compared to haloperidol-
treated patients. Sensitivity analyses showed the results to
be robust to testing of key assumptions.
CONCLUSIONS: With better outcomes and similar treat-
ment costs to haloperidol, quetiapine represents a cost-
effective treatment for schizophrenia in patients who show
only a partial response to conventional antipsychotics.
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OBJECTIVE: The purpose of this analysis was to de-
scribe and compare patterns of comorbidities and copre-
scribing among depressed patients treated with SSRIs
